Furthermore, we previously demonstrated that the disruption of leptin signaling with PEG-LPrA2 markedly reduced the growth of tumors in mouse models of syngeneic and human breast cancer xenografts [25], [26]. The gene discussed is LEP; the disease is breast carcinoma.